- Home
- VNRX vs CGTX Comparison
VNRX vs CGTX Comparison
Compare VNRX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNRX
- CGTX
- Stock Information
- Founded
- VNRX N/A
- CGTX 2007
- Country
- VNRX United States
- CGTX United States
- Employees
- VNRX N/A
- CGTX N/A
- Industry
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VNRX Health Care
- CGTX Health Care
- Exchange
- VNRX Nasdaq
- CGTX Nasdaq
- Market Cap
- VNRX 64.8M
- CGTX 53.4M
- IPO Year
- VNRX N/A
- CGTX 2021
- Fundamental
- Price
- VNRX $0.63
- CGTX $1.54
- Analyst Decision
- VNRX Strong Buy
- CGTX Strong Buy
- Analyst Count
- VNRX 4
- CGTX 3
- Target Price
- VNRX $3.50
- CGTX $2.83
- AVG Volume (30 Days)
- VNRX 200.3K
- CGTX 8.0M
- Earning Date
- VNRX 11-13-2025
- CGTX 11-12-2025
- Dividend Yield
- VNRX N/A
- CGTX N/A
- EPS Growth
- VNRX N/A
- CGTX N/A
- EPS
- VNRX N/A
- CGTX N/A
- Revenue
- VNRX $1,319,252.00
- CGTX N/A
- Revenue This Year
- VNRX $274.46
- CGTX N/A
- Revenue Next Year
- VNRX $212.60
- CGTX N/A
- P/E Ratio
- VNRX N/A
- CGTX N/A
- Revenue Growth
- VNRX 35.10
- CGTX N/A
- 52 Week Low
- VNRX $0.40
- CGTX $0.22
- 52 Week High
- VNRX $0.94
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- VNRX 46.17
- CGTX 40.63
- Support Level
- VNRX $0.57
- CGTX $2.33
- Resistance Level
- VNRX $0.73
- CGTX $2.60
- Average True Range (ATR)
- VNRX 0.05
- CGTX 0.34
- MACD
- VNRX -0.00
- CGTX -0.14
- Stochastic Oscillator
- VNRX 37.56
- CGTX 5.95
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.